We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · July 26, 2021

Dabrafenib and Trametinib Exposure Efficacy and Tolerance in Metastatic Melanoma Patients

Cancer Chemotherapy and Pharmacology


Additional Info

Cancer Chemotherapy and Pharmacology
Dabrafenib and Trametinib Exposure-Efficacy and Tolerance in Metastatic Melanoma Patients: A Pharmacokinetic–Pharmacodynamic Real-Life Study
Cancer Chemother. Pharmacol. 2021 May 31;[EPub Ahead of Print], L Goldwirt, B Louveau, B Baroudjian, C Allayous, F Jouenne, L Da Meda, LT Vu, H Sauvageon, F Herms, J Delyon, C Lebbé, S Mourah

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading